Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Shares Outstanding (Diluted Average) (2019 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Shares Outstanding (Diluted Average) readings, the most recent being $82.4 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 8.23% to $82.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $82.4 million, a 8.23% increase, with the full-year FY2025 number at $79.0 million, up 10.58% from a year prior.
  • Shares Outstanding (Diluted Average) hit $82.4 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $79.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $82.4 million in Q1 2026 to a low of $69.1 million in Q1 2022.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $71.1 million (2024), compared with a mean of $72.9 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): fell 0.84% in 2024 and later grew 10.58% in 2025.
  • Kiniksa Pharmaceuticals International's Shares Outstanding (Diluted Average) stood at $70.4 million in 2022, then rose by 2.13% to $71.9 million in 2023, then fell by 0.69% to $71.4 million in 2024, then increased by 10.58% to $79.0 million in 2025, then increased by 4.34% to $82.4 million in 2026.
  • The last three reported values for Shares Outstanding (Diluted Average) were $82.4 million (Q1 2026), $79.0 million (Q4 2025), and $78.0 million (Q3 2025) per Business Quant data.